ODM-208, a novel, small-molecule CYP11A1 inhibitor, demonstrates strong inhibition of steroid biosynthesis and antitumor activity in castration-resistant prostate cancer (CRPC) model.

被引：0
|
作者：
Karimaa, Mari [1 ]
Kettunen, Henna [1 ]
Ramela, Meri [1 ]
Mansikka-Savolainen, Suvi [1 ]
Chrusciel, Marcin [1 ]
Simola, Outi [1 ]
Taavitsainen, Paivi [1 ]
Wohlfahrt, Gerd [1 ]
Rummakko, Petteri [1 ]
Vuorela, Annamari [1 ]
Fizazi, Karim [2 ]
Oksala, Riikka [1 ]
机构：
[1] Orion Corp, Espoo, Finland
[2] Inst Gustave Roussy, Villejuif, France
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1250
引用
收藏
页数：2
相关论文
共 22 条
  • [1] ODM-208, a novel CYP11A1-inhibitor as a therapeutic approach for the treatment of castration-resistant prostate cancer
    Oksala, R.
    Karimaa, M.
    Ramela, M.
    Riikonen, R.
    Huhtaniemi, R.
    Rummakko, P.
    Wohlfahrt, G.
    Vuorela, A.
    Mustonen, M. V.
    Kallio, P.
    ANNALS OF ONCOLOGY, 2017, 28
  • [2] Opevesostat (MK-5684/ODM-208), an oral CYP11A1 inhibitor, in metastatic castration-resistant prostate cancer (mCRPC): Updated CYPIDES phase II results
    Fizazi, K.
    Roubaud, G.
    Bernard-Tessier, A.
    Gravis, G.
    Flechon, A.
    Ratta, R.
    Barthelemy, P.
    Jones, R. J.
    Parikh, O. A.
    Hussain, A.
    van der Voet, J. C. M.
    Cook, N.
    Tanner, M. M. E.
    Jones, R. H.
    Garratt, C.
    Ikonen, T.
    Pohjanjousi, P.
    Poehlein, C. H.
    Antonarakis, E. S.
    ANNALS OF ONCOLOGY, 2024, 35 : S968 - S968
  • [3] Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer
    St-Laurent, Marie-Pier
    Black, Peter C.
    EUROPEAN UROLOGY, 2024, 86 (02) : 185 - 186
  • [4] SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, demonstrates strong antitumor effects and Wnt pathway inhibition in castration-resistant prostate cancer (CRPC) models
    Bossard, Carine
    Cruz, Nathalia
    Chiu, Kevin
    Eastman, Brian
    Mak, Chi Ching
    Sunil, K. C.
    Bucci, Gail
    Stewart, Josh
    Phalen, Timothy J.
    Cha, Steven
    CANCER RESEARCH, 2020, 80 (16)
  • [5] MK-5684 (ODM-208), a CYP11A1 inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) with and without AR-LBD mutations: CYPIDES phase 2 results.
    Fizazi, Karim
    Roubaud, Guilhem
    Bernard-Tessier, Alice
    Gravis, Gwenaelle
    Flechon, Aude
    Ratta, Raffaele
    Barthelemy, Philippe
    Jones, Robert J.
    Parikh, Omi
    Hussain, Arif
    van der Voet, Hans
    Cook, Natalie
    Peters, Niamh
    Tanner, Minna
    Jones, Robert Hugh
    Garratt, Chris
    Pohjanjousi, Pasi
    Ikonen, Tarja
    Poehlein, Christian Heinrich
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 159 - 159
  • [6] Impact of activating androgen receptor (AR) mutations on AR sensitivity to alternative ligands and response to ODM-208, a selective, first-in-class CYP11A1 inhibitor, in patients with advanced metastatic castration-resistant prostate cancer (mCRPC).
    Bernard-Tessier, Alice
    Utriainen, Tapio
    Cook, Natalie
    Barthelemy, Philippe
    Lallous, Nada
    Gleave, Martin
    Ikonen, Tarja
    Riikonen, Reetta
    Pohjanjousi, Pasi
    Garratt, Chris
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] ODM-204, a novel dual inhibitor of CYP17A1 and androgen receptor for the treatment of castration-resistant prostate cancer.
    Kallio, Pekka
    Oksala, Riikka
    Moilanen, Anu
    Riikonen, Reetta
    Rummakko, Petteri
    Malmstrom, Chira
    Mustonen, Mika V. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [8] Discovery of INV-9956, an orally available and highly selective Cyp11A1 inhibitor for the treatment of castration-resistant prostate cancer with drug resistant AR mutations
    Bai, Chang
    Chen, Danqi
    Xia, Zilei
    Huang, Shujuan
    Lin, LIshan
    Zeng, Zhaopie
    Su, Jing
    Sun, Yongkui
    CANCER RESEARCH, 2024, 84 (06)
  • [9] ODM-204: A novel dual inhibitor of CYP17A1 and androgen receptor for the treatment of castration-resistant prostate cancer-Preclinical data.
    Oksala, Riikka
    Moilanen, Anu
    Riikonen, Reetta
    Rummakko, Petteri
    Huhtaniemi, Riikka
    Kallio, Pekka
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [10] ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer
    Peltola, Katriina J.
    Bono, Petri
    Jones, Robert Hugh
    Vjaters, Egils
    Nykanen, Pirjo
    Vuorela, Annamari
    Oksala, Riikka
    Pohjanjousi, Pasi
    Mustonen, Mika V. J.
    Fizazi, Karim
    Massard, Christophe
    EUROPEAN UROLOGY FOCUS, 2020, 6 (01): : 63 - 70
123